EQL Pharma AB (publ) (STO:EQL)
26.30
+1.15 (4.57%)
At close: Aug 14, 2026
EQL Pharma AB Revenue
EQL Pharma AB had revenue of 106.91M SEK in the quarter ending June 30, 2026, a decrease of -0.29%. This brings the company's revenue in the last twelve months to 432.36M, up 8.65% year-over-year. In the fiscal year ending March 31, 2026, EQL Pharma AB had annual revenue of 432.66M with 15.83% growth.
Revenue (ttm)
432.36M
Revenue Growth
+8.65%
P/S Ratio
1.80
Revenue / Employee
6.65M
Employees
23
Market Cap
776.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 432.66M | 59.15M | 15.83% |
| Mar 31, 2025 | 373.52M | 109.35M | 41.39% |
| Mar 31, 2024 | 264.17M | 4.26M | 1.64% |
| Mar 31, 2023 | 259.91M | -149.84M | -36.57% |
| Mar 31, 2022 | 409.75M | 230.61M | 128.73% |
| Mar 31, 2021 | 179.14M | 107.11M | 148.71% |
| Mar 31, 2020 | 72.03M | 22.27M | 44.77% |
| Mar 31, 2019 | 49.76M | 21.17M | 74.08% |
| Mar 31, 2018 | 28.58M | 7.05M | 32.72% |
| Dec 31, 2017 | 21.54M | -6.67M | -23.63% |
| Dec 31, 2016 | 28.20M | 1.33M | 4.94% |
| Dec 31, 2015 | 26.87M | 9.28M | 52.78% |
| Dec 31, 2014 | 17.59M | -4.58M | -20.67% |
| Dec 31, 2013 | 22.17M | 5.50M | 32.99% |
| Dec 31, 2012 | 16.67M | 4.91M | 41.69% |
| Dec 31, 2011 | 11.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.58B |
| Cinclus Pharma Holding AB | 67.51M |
| Cereno Scientific AB | 66.82M |
| Nanexa AB | 54.41M |
| Enzymatica AB | 51.93M |
| Newbury Pharmaceuticals AB | 35.02M |
| Orexo AB | 16.60M |
| Moberg Pharma AB | 14.59M |
EQL Pharma AB News
- 8 days ago - EQL Pharma AB Transcript: Q1 26/27 - Transcripts
- 8 days ago - EQL Pharma AB Quarterly report: Q1 2027 - Filings
- 8 days ago - EQL Pharma AB Slides: Q1 2027 - Filings
- 3 months ago - EQL Pharma AB Transcript: Q4 25/26 - Transcripts
- 3 months ago - EQL Pharma AB Quarterly report: Q4 2026 - Filings
- 3 months ago - EQL Pharma AB Annual report: Q4 2026 - Filings
- 6 months ago - EQL Pharma AB Transcript: Q3 25/26 - Transcripts
- 6 months ago - EQL Pharma AB Quarterly report: Q3 2026 - Filings